Phase 2 Trial of 5-Fluorouracil, Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-Positive Disease) During 1st Line Treatment of Advanced Esophageal and Gastric Adenocarcinoma

Protocol No
WON-UW19029
Principal Investigator
Aditya Shreenivas
Phase
II
Summary
This study is being done to find out whether adding a drug called liposomal irinotecan to standard combination therapy will be more active against advanced EGA than standard treatment. Liposomal irinotecan is a new chemotherapy drug that has been approved by the FDA to treat pancreatic cancer. Researchers think that combining liposomal irinotecan with a standard combination chemotherapy regimen will be beneficial against EGA as well. Combining three chemotherapy drugs has been shown to be more potent against this cancer in the past. However, older drugs have had more side effects. Researchers hope that the new combination will be active and less toxic. However, this treatment may have bad side effects, even if it shrinks tumors.
Description
P2 5-FU, Oxaliplatin & Liposomal Irinotecan (Nal-IRI) in 1st Line Advanced Esophageal & Gastric Cancers
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL